Previously resident in a JLabs facility in Lowell MA, Third Pole - also dba Third Pole Therapeutics - is structured around development of next generation life-saving cardiopulmonary therapies. Building on the teams legacy in inhaled nitric oxide (NO) - the current standard of care - to address development of the next generation life-saving heart and lung therapies, the firm's first therapies are delivered by a simple, convenient, economical, and lightweight device capable of generating nitric oxide from air on-demand and on-site which potentially eliminates the need for large compressed gas cylinders. It is management's expressed judgment that their novel approach of creating new on-demand offers the promise of new market creation by enabling the worldwide use of inhaled NO in settings outside those of of acute care.
